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MULTIPLE MYELOMA WITH ADVANCED 
BONE DISEASE AND LOW TUMOR BURDEN 
– DIFFERENT CLINICAL PRESENTATION BUT SIMILAR 
OUTCOME AFTER BORTEZOMIB-BASED THERAPY 
AND RADIOTHERAPY
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SUMMARY – Th ere is a small but well recognized group of patients with multiple myeloma 
(MM), characterized by multiple bone lesions and low tumor burden, the so-called macrofocal form 
of MM (MF-MM). Th e aim of the study was to analyze the incidence, clinical manifestation, thera-
peutic outcome and prognosis of patients with MF-MM treated with bortezomib-based therapy and 
radiotherapy, in comparison to classic MM. Th ere were 148 MM patients treated with bortezomib-
based regimens, with 15 (10.1%) of them meeting the criteria for MF-MM. Comparative analysis 
involved disease- and therapy-related variables and markers of bone metabolism in MF-MM and 
classic MM groups. Event-free survival (EFS) and median survival (MS) were analyzed. Patients in 
MF-MM and classic MM groups had similar mean age and sex distribution. Patients with MF-MM 
had advanced myeloma bone disease (MBD), signifi cantly lower clonal plasma cell infi ltration in bone 
marrow, and lower paraprotein level. Th ese patients were predominantly in an early International 
Staging System stage, showed non-secretory and light-chain variants, and signifi cant association with 
extramedullary plasmacytomas. EFS was 20 months in MF-MM group versus 13 months in classic 
MM group (nonsignifi cant diff erence). MS was 42 months in both MF-MM and classic MM groups. 
MF-MM presents with imbalance of the minimal tumor burden and massive bone involvement. 
Along with advanced skeletal manifestations, these patients showed features of preserved bone mar-
row and no end-organ damages. Following bortezomib-based therapy and radiotherapy, the EFS and 
MS did not diff er between MF-MM and classic MM groups.
Key words: Multiple myeloma; Bone and bones – pathology; Bortezomib – therapeutic use; Radiotherapy
Correspondence to: Vesselina Goranova-Marinova, MD, Clinical 
Department of Hematology, Sv. Georgi University Hospital and 
Plovdiv Medical University, 15A Vassil Aprilov Blv., 4002 Plovdiv, 
Bulgaria
E-mail: vesselina_goranova@yahoo.com
Received March 16, 2015, accepted April 3, 2017
Introduction
Generalized bone lesions aff ect clinical evolution 
of multiple myeloma (MM), create diffi  culties in de-
fi ning the stage of the disease, its therapeutic outcome 
does not always follow the outcome of medullary dis-
ease, and myeloma bone disease (MBD) disables pa-
tients and deteriorates their prognosis. Usually, severe 
MBD refl ects an advanced MM with high percentage 
of bone marrow plasma cell infi ltration, high level of 
serum/urine paraprotein and end-organ damages.
A small proportion of MM patients present with 
multiple, generalized bone lesions and low tumor bur-
den, i.e. low percentage of monoclonal plasma cells in 
bone marrow and low production of paraprotein or 
non-secretory variants. Th is group is called by some 
authors multifocal form of MM (MF-MM). Th e same 
term was used in our analysis. Th ere are limited data in 
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the literature on therapeutic options, outcome, moni-
toring of therapeutic response, prognostic factors and 
survival of these patients.
Th e aim of the study was to analyze the incidence, 
clinical manifestation, therapeutic outcome and prog-
nosis of patients with MF-MM treated with bortezo-
mib-based therapy and radiotherapy in comparison to 
classic MM.
Patients and Methods
During the period from January 2008 till June 
2014, 148 patients with MM treated with bortezo-
mib-based regimens were retrospectively studied. 
Th eir mean age was 60.16±9.43 years and the male to 
female ratio was 1.05:1. Th e criteria for MF-MM 
were: MBD grade 2 and 3; clonal plasma cell infi ltra-
tion in bone marrow less than 20%; and paraprotein in 
serum <25g/L, paraprotein in urine <1.0 g/24 h by 
protein electrophoresis/immune fi xation. Fifteen of 
148 (10.1%) patients fulfi lled the criteria for MF-MM 
(Table 1). Clinical stage was defi ned according to the 
International Staging System (ISS). Bone lesions were 
assessed by conventional x-ray of axial skeleton or 
computed tomography (CT) scan and magnetic reso-
nance imaging (MRI) at the sites of interest. MBD 
was graded in four grades: 0 – no lytic bone lesions or 
osteoporosis; 1 – osteolytic lesions at <3 sites +/- os-
teoporosis; 2 – multiple bone lesions at >3 sites and/or 
pathologic fractures; and 3 – multiple lytic lesions and 
destructions of skeletal segments. All 148 patients 
were treated with bortezomib-based regimens in 21-
day cycles. Bortezomib (Millennium Pharmaceuticals, 
Inc., Th e Takeda Oncology Company, Cambridge, 
Massachusetts, USA) was administered in a dose of 
1.3 mg/m2 on days 1, 4, 8 and 11, and was combined 
with dexamethasone (VelDex) in 31 (20.9%), with cy-
clophosphamide (CyBorD) in 54 (36.5%) and with 
anthracycline (PAD) in 14 (9.5%) patients. Bortezo-
mib regimen was administered as fi rst line therapy in 
53 (36.1%), as second line therapy in 51 (34.7%) and 
as >second line therapy in 43 (29.1%) patients. Five 
(33.33%) patients underwent high-dose therapy with 
melphalan 200 mg/m2 with autologous stem-cell 
transplantation. Radiotherapy of lytic bone lesions, 
pathologic factures and soft tissue plasmacytomas was 
incorporated in therapeutic regimen when indicated. 
Patients underwent radiotherapy on a linear accelera-
tor Siemens Mevatron Primus. Two main schemes of 
irradiation were used: 2×8.5 Gy with an interval of 72 
hours and 5×4 Gy. Th ree patients received irradiation 
at one of the aff ected sites with 1 fraction of 8 Gy as a 
single dose. Comparative analysis of the disease and 
therapy related variables and markers of bone metabo-
lism (serum Ca and alkaline phosphatase, AP) was 
performed in patients with MF-MM and classic MM. 
As patients with MF-MM represent a unique prob-
lem in terms of therapeutic response because many of 
them lack a detectable monoclonal protein in serum 
and/or urine and myeloma cell infi ltration in bone 
marrow is initially low, the event free survival (EFS) 
and median survival (MS) were assessed for analysis of 
outcome. Th erapeutic response of MBD was assessed 
by the dynamics of bone pain, dynamics in the size of 
bone lesions and changes in the level of serum Ca and 
AP. Statistical analysis was performed by use of SPSS 
v. 18.0, using descriptive analysis, analysis of variation 
and analysis of alternatives, and independent samples 
T-test for independent samples. Th e method of Ka-
plan-Maier with log rank test was used for analysis of 
EFS and MS.
Results
Patients in the MF-MM and classic MM groups 
had similar mean age (60.6±7.32 vs. 60.11±9.67 years) 
and similar sex distribution (Table 2).
Clinical characteristics of MF-MM patients 
in comparison to classic MM
By the principle of selection, in comparison with 
classic MM patients, all patients with MF-MM had 
Table 1. Clinical characteristics of MF-MM patients 















0.53±0.26 1.47±0.23  0.01
MM = multiple myeloma; MF-MM = macrofocal MM
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advanced MBD, i.e. grade 2 and grade 3 was recorded 
in 5 (100%) and 54 (40.9%) patients, respectively 
(p<0.001); MF-MM patients also had signifi cantly 
lower clonal plasma cell infi ltration in bone marrow 
and lower level of paraprotein in serum and/or urine. 
Th ese patients were predominantly in an early ISS 
stage and showed a signifi cant predominance of non-
secretory and light-chain variants (Figs. 1 and 2). In 
the group of MF-MM, there were no patients with 
severe anemia, while the share of patients with renal 
failure, hypoalbuminemia and elevated beta
2
-micro-
globulin (β2M; >3.5 mg/L) was signifi cantly lower. 
MF-MM was signifi cantly associated with extramed-
ullary plasmacytomas (Table 2). Th e levels of hemo-
globin and albumin were also signifi cantly higher, 
while β2M and creatinine were signifi cantly lower 
than in classic MM (Table 3). Th ere was no between-
group diff erence in the levels of Ca and AP.
Th erapeutic outcome
Th e mean number of bortezomib cycles was 
6.07±1.06 in MF-MM and 6.73±0.49 in classic MM 
group (NS). Patients with MF-MM were irradiated 
signifi cantly more frequently than those with classic 
MM (14 (93.3%) vs. 65 (49.9%); p<0.001) and MF-
MM had a signifi cantly higher mean number of irra-
diations (2.53±0.34 vs. 0.56±0.54; p<0.001). Th erapy 
alleviated bone pain in all patients, and in 9/15 pa-
tients complete resolution of symptoms occurred. In 3 
patients, reduction in the size of bone lesions was ob-
served. Extramedullary formations were reduced in all 
patients, and in 11/15 patients they completely disap-
peared (fi brous tissue on enhanced CT scan). After 
therapy, a signifi cant increase in the level of AP and 
decrease in the levels of Ca, LDH and β2M was re-
corded (Table 4). Th ere was a trend of longer EFS of 
20 months (95% confi dence interval (95% CI): 18.152-
21.848) in MF-MM group versus 13 months (95% CI: 
10.213-15.787) in classic MM group but the diff er-
ence was not statistically signifi cant (Fig. 3). MS was 
42 months in both MF-MM and classic MM groups: 
MF-MM 95% CI: 18.38-65.62 and classic MM 95% 
CI: 37.04-46.96.
Toxicity
Th ere was no signifi cant diff erence in hematologic 
and non-hematologic toxicity between the two groups, 
Table 2. Patient characteristics in MF-MM and classic 
MM groups
Parameter, n (%) MF-MM Classic MM p-value







Renal failure 1 (6.7) 49 (37.1) 0.013
Hb <80 g/L 0 28 ( 22.2) 0.03
Albumin <30 g/L 1 (6.7) 43 (34.1) 0.012
LDH >480 U/L 4 (26.7) 29 (23.0) NS
Serum Ca 4 (26.7) 22 (17.5) NS
AP <100U/L 3 (20.0) 34 (32.4) NS
β2M >3.5 mg/L 1 (6.7) 50 (40.0) 0.012
Extramedullary 
plasmacytomas
9 (60.0) 15 (16.5) <0.001
MM = multiple myeloma; MF-MM = macrofocal MM; Hb = he-
moglobin; LDH = lactate dehydrogenase; AP = alkaline phospha-
tase; β2M = beta
2
-microglobulin; NS = nonsignifi cant
Fig. 1. Distribution according to the International 
Staging System (ISS) stage.
MM = multiple myeloma; MF-MM = macrofocal MM
Fig. 2. Distribution according to immunologic variant.
MM = multiple myeloma; MF-MM = macrofocal MM
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although patients with MF-MM had undergone more 
irradiation (Table 5). Th e most common side eff ect 
was peripheral polyneuropathy: 5 (33.3%) versus 46 
(35.9%) in the MF-MM and classic MM group, re-
spectively. Th ere were no patients with polyeuropathy 
grade 3 and 4.
Discussion
Intensive bone resorption is the earliest event in 
the evolution of MM1, while the increased number of 
osteoclasts/mm2 per trabecular bone surface is the most 
solid marker of monoclonal gammopathy of undeter-
mined signifi cance (MGUS) transformation into ac-
tive MM2. Nowadays, the pathogenic mechanisms of 
bone resorption are a subject of profound research. 
Both the osteolytic lesions at the sites of plasma cell 
infi ltration and distant humoral demineralization of 
Table 3. Mean values of some major parameters 






Hb 128.81±7.33 96.5±1.7 <0.001
Creatinine 84.67±9.23 167.17±15.19 <0.001
LDH 417.00±23.74 395.29±14.47  NS
Albumin 40.67±1.41 34.15±0.63  0.01
Β2M 2.99±0.40 7.13±0.57  <0.001
Serum Ca 2.58±0.12 4.24±1.81 NS
AP 165.67±18.15 147.39±5.88 NS
MM = multiple myeloma; MF-MM = macrofocal MM; Hb = he-
moglobin; LDH = lactate dehydrogenase; β2M = beta
2
-microglob-
ulin; AP = alkaline phosphatase; NS = nonsignifi cant
Table 4. Dynamics of bone metabolism parameters 







AP 180.67±26.77 207.07±24.45 0.026
Ca 2.45±0.06 2.31±0.04 0.002
LDH 482.67±43.29 410.33±34.29 0.05
β2M 2.67±0.34 1.67±0.12 0.003
MM = multiple myeloma; MF-MM = macrofocal MM; AP = alka-




Table 5. Hematologic and non-hematologic toxicity
Toxicity MF-MM Classic MM p-value
Polyneuropathy 5 (33.3) 46 (35.9) NS
Th rombocytopenia 1 (6.7) 25 (19.2) NS
Neutropenia 2 (13.4) 11 (8.5) NS
Hypotension 2 (13.4) 13 (15.7) NS
Gastrointestinal 4 (26.7) 37 (28.0) NS
NS = nonsignifi cant
Fig. 3. Event-free survival in patients with MF-MM 
and classic MM.
MM = multiple myeloma; MF-MM = macrofocal MM
Fig. 4. Median survival in patients with MF-MM and 
classic MM.
MM = multiple myeloma; MF-MM = macrofocal MM
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bone are a result of the action of osteolytic cytokines 
secreted or induced by myeloma cells. A great number 
of osteolytic substances or ‘osteoclast activating factors’ 
have been discussed in the literature, e.g., tumor necro-
sis factor α (TNF-α), TNF-β, interleukin 1b (IL-1b), 
IL-6, IL-10, IL-11, hepatocyte growth factor (HGF), 
matrix metalloproteinases (MMP) 2, 7, 9, and macro-
phage infl ammatory protein (MIP-1α, MIP-1β)3. 
Nowadays, the critical role of the osteoprotegerin/re-
ceptor activator of NF-jB ligand (OPG/RANKL) sys-
tem in bone remodeling in physiologic and pathologic 
conditions and in MM has been proven in many pre-
clinical settings and in myeloma patients. Th e balance 
of the system is shifted towards RANKL overexpres-
sion and OPG suppression resulting in increased bone 
resorption and decreased bone formation. Th e role of 
Dickkopf protein-1 (DKK-1) as an inhibitor of osteo-
blast function is also important4-7. Th e negative quanti-
tative balance of bone remodeling is a result of en-
hanced osteoclast function and suppressed osteoblast 
function refl ected by the level of bone-specifi c AP. 
Until the era of novel agents, almost all drugs attacked 
the factors responsible for osteoclast activation, and no 
drug stimulated osteoblast function. With the intro-
duction of bortezomib in clinical practice, it was prov-
en that proteasome inhibition not only suppresses 
bone resorption but also aff ects positively osteoblast 
function8. Th ere are data on a decrease of the markers 
of bone resorption and increase of the markers of bone 
synthesis in MM after treatment with bortezomib9.
Patients with MF-MM present a specifi c feature, 
imbalance of the minimal tumor burden on the one 
hand, and massive bone involvement, i.e. multiple os-
teolytic lesions, fractures, and destructions of skeletal 
segments on the other hand. A parallel to light-chain 
(AL) amyloidosis is possible: in AL amyloidosis, low 
plasma cell tumor mass produces light chains with 
prominent tissue tropism; in MF-MM form, a higher 
expression of osteolytic cytokines with high bone im-
pact is suspected. Although MF-MM form is rare, it 
poses signifi cant diffi  culties in diagnosis, staging, 
prognostic assessment and therapy of patients. Th ese 
patients share some common characteristics such as 
low tumor burden, i.e. low percentage of clonal plasma 
cells in bone marrow, and low production of serum 
and/or urine paraprotein, with a predominance of the 
non-secretory and light-chain variants. Minimal sup-
pression of hematopoiesis and low M-grade with rare 
immune paresis is refl ected by the unusual normal lev-
els of hemoglobin10, platelets and β2M, and preserved 
renal function. Th e most prominent feature of MF-
MM is massive involvement of skeleton and frequent 
associations with soft tissue plasmacytomas11. Th ere 
are contradictory data concerning the outcome of 
these patients. Smith et al. report that patients with 
non-secretory MM and multiple lytic bone lesions 
have a signifi cantly shorter MS of 21 months versus 42 
months12. In a retrospective study, Dimopoulous et al. 
found the incidence of MF-MM of 10/56 in young 
MM patients for a 20-year period, therapeutic re-
sponse rate of 55%, and unreached MS. According to 
the authors, these patients had low tumor burden and 
better outcome with calculated MS of 8 years13. Kumar 
et al. describe atypical presentations of non-secretory 
MM and their frequent association with multiple 
bone lesions and plasmacytomas. Th ey proved similar 
outcome and prognosis in these patients after autolo-
gous stem cell transplantation compared to the classic 
MM form11. Our patients shared the presenting fea-
tures reported by most of the authors with identical 
MS in the two groups after therapy with bortezomib-
based regimens and radiotherapy. Th e trend of longer 
PFS in our analysis may have been a refl ection of the 
late diagnosis of relapse due to the absence or low 
grade M-component. Th e dynamics of the bone me-
tabolism markers of Ca and AP after therapy with 
bortezomib-based regimens plus radiotherapy refl ect-
ed improved osteoblast and osteoclast function. While 
the rapid therapeutic response and improvement in 
the markers of MM activity are typical after bortezo-
mib therapy, there are few data on the reduction in the 
size of ostelytic bone lesions and increase in the bone 
fraction of AP. Zangari et al. found a 25% increase of 
AP level above the baseline, which correlated with 
high CR + PR rates and longer time to progression14. 
Heider et al. demonstrated signifi cant elevation of os-
teocalcin and bone fraction of AP in parallel to reduc-
tion of collagen cross-links15. Th e mechanisms of im-
provement of bone lesions once they occur are still 
under investigation. Nowadays, the role of MRI and 
positron emission tomography-CT (PET-CT) in the 
assessment of MF-MM is proven as they diff erentiate 
plasma cell infi ltration of bone marrow, osteolytic bone 
lesions and soft tissue plasmacytomas. Th ese are the 
recommended methods for monitoring therapeutic 
 response, with exceptional signifi cance in non-secreto-
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ry MM, soft tissue plasmacytomas, as well as in the 
MF-MM group.
Myeloma tumor mass, transformed bone marrow 
microenvironment, multiple cell populations of osteo-
clasts, osteoblasts, osteocytes, stromal cells, endothelial 
cells, cell-to-cell interactions and humoral factors are 
being attacked with ‘novel’ agents. Hopefully, it is a 
matter of near future to disrupt the ‘vicious circle’ of 
MM, i.e. as MM is more active, bone resorption is 
more intensive, and vice versa.
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Sažetak
MULTIPLI MIJELOM S UZNAPREDOVALOM KOŠTANOM BOLEŠĆU 
I NISKIM TUMORSKIM OPTEREĆENJEM – RAZLIČITE KLINIČKE MANIFESTACIJE 
ALI SLIČAN ISHOD NAKON TERAPIJE NA OSNOVI BORTEZOMIBA I RADIOTERAPIJE
V. Goranova-Marinova, M. Yaneva, T. Deneva i S. Goranov
Postoji manja, ali dobro prepoznata skupina bolesnika s multiplim mijelomom (MM) koja je obilježena višestrukim 
oštećenjima kostiju i niskim tumorskim opterećenjem, tzv. makrofokalni oblik MM (MF-MM). Cilj ovoga istraživanja bio 
je analizirati incidenciju, kliničke manifestacije, ishod terapije i prognozu u bolesnika s MF-MM liječenih terapijom na 
 osnovi bortezomiba i radioterapijom u usporedbi s klasičnim MM. Ukupno je 148 bolesnika s MM liječeno terapijom na 
osnovi bortezomiba, od kojih je 15 (10,1%) ispunjavalo kriterije za MF-MM. Usporedbena analiza obuhvatila je varijable 
povezane s bolešću i terapijom te biljege koštanog metabolizma u skupinama bolesnika s MF-MM i klasičnim MM. Anali-
zirano je preživljenje bez ispada (event-free survival, EFS) te medijan preživljenja (median survival, MS). Distribucija prema 
srednjoj dobi i spolu bila je slična u skupinama s MF-MM i klasičnim MM. Bolesnici s MF-MM imali su uznapredovalu 
mijelomsku bolest kostiju, značajno niži stupanj infi ltracije klonskih plazma stanica u koštanoj srži te nižu razinu parapro-
teina. Ovi bolesnici bili su pretežito u ranom stadiju prema Međunarodnom sustavu stadija bolesti, imali su ne-sekrecijske i 
lako-lančane varijante te značajnu pridruženost ekstramedularnih plazmacitoma. EFS je bio 20 mjeseci u skupini s MF-MM 
prema 13 mjeseci u skupini s klasičnim MM (neznačajna razlika). MS je bio 42 mjeseca u objema skupinama bolesnika. 
MF-MM se manifestirao kao neravnoteža minimalnog tumorskog opterećenja i velikim zahvaćanjem kostiju. Uz uzna-
predovale skeletne manifestacije, ovi bolesnici su imali očuvanu koštanu srž i izostanak oštećenja krajnjih organa. Nakon 
terapije zasnovane na bortezomibu i radioterapije nije bilo razlike u EFS i MS između skupina bolesnika s MF-MM i 
 klasičnim MM.
Ključne riječi: Multipli mijelom; Kosti – patologija; Bortezomib – terapijska primjena; Radioterapija
